Immunosenescence is also associated with reduced response to anti-TNF-α biologics (such as infliximab) in IBD patients, with mechanisms involving B cell dysfunction, T cell exhaustion, and the effects of the chronic inflammatory environment (Faye et al., 2024). The gene discussed is TNF; the disease is inflammatory bowel disease.